G&S Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.63M | Buy |
18,392
+150
| +0.8% | +$32.3K | 1.34% | 19 |
|
|
2026
Q1 | $3.97M | Buy |
18,242
+554
| +3% | +$123K | 1.39% | 18 |
|
|
2025
Q4 | $4.04M | Sell |
17,688
-1,159
| -6% | -$264K | 1.43% | 16 |
|
|
2025
Q3 | $4.36M | Buy |
18,847
+93
| +0.5% | +$18.9K | 1.61% | 12 |
|
|
2025
Q2 | $3.48M | Buy |
18,754
+305
| +2% | +$56.7K | 1.38% | 17 |
|
|
2025
Q1 | $3.87M | Sell |
18,449
-2,819
| -13% | -$548K | 1.64% | 13 |
|
|
2024
Q4 | $3.78M | Buy |
21,268
+15,485
| +268% | +$2.85M | 1.56% | 14 |
|
|
2024
Q3 | $1.14M | Buy |
5,783
+52
| +0.9% | +$9.71K | 0.48% | 67 |
|
|
2024
Q2 | $963K | Sell |
5,731
-107
| -2% | -$17.7K | 0.42% | 73 |
|
|
2024
Q1 | $1.06M | Sell |
5,838
-82
| -1% | -$14.1K | 0.47% | 72 |
|
|
2023
Q4 | $917K | Buy |
5,920
+135
| +2% | +$19.7K | 0.44% | 73 |
|
|
2023
Q3 | $862K | Buy |
5,785
+67
| +1% | +$9.84K | 0.44% | 73 |
|
|
2023
Q2 | $770K | Sell |
5,718
-2,554
| -31% | -$375K | 0.37% | 76 |
|
|
2023
Q1 | $1.32M | Buy |
8,272
+3,175
| +62% | +$485K | 0.58% | 54 |
|
|
2022
Q4 | $824K | Buy |
5,097
+495
| +11% | +$75.9K | 0.36% | 73 |
|
|
2022
Q3 | $618K | Buy |
4,602
+327
| +8% | +$46.9K | 0.33% | 72 |
|
|
2022
Q2 | $655K | Buy |
4,275
+223
| +6% | +$34.1K | 0.39% | 65 |
|
|
2022
Q1 | $657K | Sell |
4,052
-69
| -2% | -$10K | 0.35% | 77 |
|
|
2021
Q4 | $558K | Buy |
4,121
+219
| +6% | +$25.9K | 0.28% | 85 |
|
|
2021
Q3 | $421K | Buy |
3,902
+347
| +10% | +$39.6K | 0.23% | 87 |
|
|
2021
Q2 | $400K | Buy |
3,555
+371
| +12% | +$41.8K | 0.21% | 87 |
|
|
2021
Q1 | $345K | Buy |
3,184
+311
| +11% | +$33.3K | 0.2% | 91 |
|
|
2020
Q4 | $308K | Buy |
2,873
+32
| +1% | +$3.08K | 0.18% | 90 |
|
|
2020
Q3 | $249K | Buy |
2,841
+133
| +5% | +$12.5K | 0.18% | 78 |
|
|
2020
Q2 | $266K | Sell |
2,708
-278
| -9% | -$24.5K | 0.24% | 58 |
|
|
2020
Q1 | $227K | Buy |
2,986
+38
| +1% | +$3.24K | 0.4% | 43 |
|
|
2019
Q4 | $261K | Buy |
2,948
+133
| +5% | +$11K | 0.15% | 82 |
|
|
2019
Q3 | $213K | Buy |
2,815
+306
| +12% | +$21K | 0.12% | 68 |
|
|
2019
Q2 | $182K | Sell |
2,509
-249
| -9% | -$19.6K | 0.11% | 77 |
|
|
2019
Q1 | $222K | Buy |
2,758
+1,229
| +80% | +$101K | 0.14% | 73 |
|
|
2018
Q4 | $141K | Sell |
1,529
-35,574
| -96% | -$3.13M | 0.13% | 59 |
|
|
2018
Q3 | $3.51M | Buy |
37,103
+35,892
| +2,964% | +$3.4M | 2.42% | 16 |
|
|
2018
Q2 | $112K | Buy |
1,211
+128
| +12% | +$12.5K | 0.09% | 82 |
|
|
2018
Q1 | $102K | Buy |
1,083
+287
| +36% | +$31.5K | 0.09% | 83 |
|
|
2017
Q4 | $77K | Buy |
+796
| New | +$75K | 0.06% | 112 |
|
Other funds holding ABBV
G&S Capital's ABBV Position: Q2 2026 in Review
G&S Capital increased its AbbVie (ABBV) stake by 0.82% in Q2 2026, buying an estimated $32.3K and bringing the position to 18,392 shares worth $4.63M. The position accounts for 1.34% of the portfolio, ranked #19.
G&S Capital first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- G&S Capital held 18,392 shares of AbbVie worth $4.63M as of Q2 2026.
- G&S Capital bought 150 AbbVie shares in Q2 2026, an estimated $32.3K.
- AbbVie made up 1.34% of G&S Capital's portfolio in Q2 2026, its #19 holding.
- G&S Capital first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
- 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on G&S Capital's 13F filing for Q2 2026, filed 10 Jul 2026.